233 related articles for article (PubMed ID: 29390025)
1. Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients.
Calocer F; Dejardin O; Droulon K; Launoy G; Defer G
PLoS One; 2018; 13(2):e0191646. PubMed ID: 29390025
[TBL] [Abstract][Full Text] [Related]
2. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
[TBL] [Abstract][Full Text] [Related]
3. The influence of socioeconomic factors on access to disease modifying treatment in a Norwegian multiple sclerosis cohort.
Flemmen HØ; Simonsen CS; Broch L; Brunborg C; Berg-Hansen P; Moen SM; Kersten H; Celius EG
Mult Scler Relat Disord; 2022 May; 61():103759. PubMed ID: 35358792
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study.
Simacek KF; Ko JJ; Moreton D; Varga S; Johnson K; Katic BJ
J Med Internet Res; 2018 Oct; 20(10):e11168. PubMed ID: 30377144
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.
Bsteh G; Feige J; Ehling R; Auer M; Hegen H; Di Pauli F; Deisenhammer F; Reindl M; Berger T
Mult Scler; 2017 Aug; 23(9):1241-1248. PubMed ID: 27765877
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
Lenz F; Harms L
Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
[TBL] [Abstract][Full Text] [Related]
7. Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis.
Reyes S; Suarez S; Allen-Philbey K; Yildiz Ö; Mathews J; Anjorin G; Edwards F; Jain C; Turner B; Marta M; Gnanapavan S; Schmierer K; Giovannoni G
Mult Scler Relat Disord; 2020 Jun; 41():102024. PubMed ID: 32143179
[TBL] [Abstract][Full Text] [Related]
8. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.
Healy BC; Engler D; Gholipour T; Weiner H; Bakshi R; Chitnis T
J Neurol Sci; 2011 Apr; 303(1-2):109-13. PubMed ID: 21251671
[TBL] [Abstract][Full Text] [Related]
9. Impact of diagnosis and early treatment on the course of multiple sclerosis.
Noyes K; Weinstock-Guttman B
Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
[TBL] [Abstract][Full Text] [Related]
10. Socioeconomic status and access to multiple sclerosis treatment in Mexico.
Gómez-Figueroa E; de Saráchaga AJ; García-Estrada C; Casallas-Vanegas A; Delgado-García G; Garcia-Martinez P; Zabala-Angeles I; Marcin-Sierra M; Moreno-Torres P; Corona-Vázquez T; Rivas-Alonso V; Flores-Rivera J
Mult Scler Relat Disord; 2021 Jul; 52():102967. PubMed ID: 33934010
[TBL] [Abstract][Full Text] [Related]
11. Socioeconomic deprivation increases the risk of disability in multiple sclerosis patients.
Calocer F; Dejardin O; Kwiatkowski A; Bourre B; Vermersch P; Hautecoeur P; Launoy G; Defer G
Mult Scler Relat Disord; 2020 May; 40():101930. PubMed ID: 31982665
[TBL] [Abstract][Full Text] [Related]
12. Highly active disease and access to disease-modifying treatments in patients with relapsing-remitting multiple sclerosis in Poland.
Brola W; Adamczyk-Sowa M; Kułakowska A; Głażewska J; Smaga A; Bartosik-Psujek H
Neurol Neurochir Pol; 2022; 56(3):256-260. PubMed ID: 35766058
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
14. Natural history of relapsing remitting multiple sclerosis in a long-lasting cohort from a tertiary MS centre in Portugal.
Sá MJ; Sequeira L; Ferro D; Marcolino A; Rocha AL; Seabra M; Mendonça T; Abreu P; Guimarães J; Macedo A
Mult Scler Relat Disord; 2021 Sep; 54():103091. PubMed ID: 34246020
[TBL] [Abstract][Full Text] [Related]
15. Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options.
Jonker MF; Donkers B; Goossens LMA; Hoefman RJ; Jabbarian LJ; de Bekker-Grob EW; Versteegh MM; Harty G; Wong SL
Med Decis Making; 2020 Feb; 40(2):198-211. PubMed ID: 32065023
[No Abstract] [Full Text] [Related]
16. Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis.
Pasca M; Forci B; Mariottini A; Mechi C; Barilaro A; Massacesi L; Repice AM
Mult Scler Relat Disord; 2021 Jan; 47():102591. PubMed ID: 33142245
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis.
Bozkaya D; Livingston T; Migliaccio-Walle K; Odom T
J Med Econ; 2017 Mar; 20(3):297-302. PubMed ID: 27822961
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Hernandez L; Guo S; Kinter E; Fay M
J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
[TBL] [Abstract][Full Text] [Related]
20. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
